New Antibody-Azacitidine combo aims to boost remission in High-Risk blood cancer
Disease control
Not yet recruiting
This phase 2 trial tests whether adding bexmarilimab, an antibody that targets Clever-1, to standard azacitidine chemotherapy improves outcomes for adults with newly diagnosed higher-risk myelodysplastic syndromes (HR-MDS). Participants are randomly assigned to receive one of two…
Phase: PHASE2 • Sponsor: Faron Pharmaceuticals Ltd • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC